scispace - formally typeset
P

Philippe Lefebvre

Researcher at University of Liège

Publications -  74
Citations -  2388

Philippe Lefebvre is an academic researcher from University of Liège. The author has contributed to research in topics: Neurotrophin & Spiral ganglion. The author has an hindex of 26, co-authored 73 publications receiving 2185 citations.

Papers
More filters
Journal ArticleDOI

NT-3 and/or BDNF therapy prevents loss of auditory neurons following loss of hair cells.

TL;DR: Results show that loss of auditory neurons that occurs subsequent to a Loss of auditory hair cells can be prevented by in vivo neurotrophin therapy with either NT-3 or BDNF.
Journal ArticleDOI

Auditory Resting-State Network Connectivity in Tinnitus: A Functional MRI Study

TL;DR: The results show that there is a modification of cortical and subcortical functional connectivity in tinnitus encompassing attentional, mnemonic, and emotional networks and suggest that various regions of the brain seem involved in the persistent awareness of the phenomenon as well as in the development of the associated distress leading to disabling chronic tinnitis.
Journal ArticleDOI

Oxidative stress-induced apoptosis of cochlear sensory cells: otoprotective strategies

TL;DR: Several approaches for the prevention of auditory sensory loss from reactive oxygen species‐induced apoptosis are presented, including preventing the formation of reactive oxygenspecies; neutralizing the toxic products of membrane lipid peroxidation; and blocking the damaged sensory cells’ apoptotic pathway.
Journal ArticleDOI

Connectivity graph analysis of the auditory resting state network in tinnitus.

TL;DR: A modified functional connectivity pattern in tinnitus sufferers is shown and the role of the parahippocampal region in t Finnitus physiopathology is highlighted, pointing out the importance of the activity and connectivity pattern of the posterior cingulate cortex/precuneus region to the development of theTinnitus associated distress.
Journal ArticleDOI

Local perfusion of the tumor necrosis factor alpha blocker infliximab to the inner ear improves autoimmune neurosensory hearing loss.

TL;DR: It is demonstrated that in patients with AIED, transtympanic delivery of the TNF-α blocker infliximab once weekly for 4 weeks allowed steroids to be tapered off, resulted in hearing improvement and reduced disease relapses.